These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24970455)

  • 1. Development of novel therapy of schizophrenia in children and adolescents.
    Klein C; Bespalov A
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1531-40. PubMed ID: 24970455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for schizophrenia: an update.
    Köster LS; Carbon M; Correll CU
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):511-31. PubMed ID: 25234340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone for schizophrenia: what's different?
    Kantrowitz JT; Citrome L
    Expert Rev Neurother; 2012 Mar; 12(3):265-73. PubMed ID: 22364325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for schizophrenia.
    Biedermann F; Fleischhacker WW
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):271-82. PubMed ID: 21563991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational drugs for anxiety in patients with schizophrenia.
    Garay RP; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2015 Apr; 24(4):507-17. PubMed ID: 25423603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management.
    Kranzler HN; Cohen SD
    Child Adolesc Psychiatr Clin N Am; 2013 Oct; 22(4):727-44. PubMed ID: 24012083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone: a new drug in development for schizophrenia.
    Meyer JM; Loebel AD; Schweizer E
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1715-26. PubMed ID: 19780705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach.
    Schimmelmann BG; Schmidt SJ; Carbon M; Correll CU
    Curr Opin Psychiatry; 2013 Mar; 26(2):219-30. PubMed ID: 23364281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatment of adolescent and child schizophrenia.
    Young CM; Findling RL
    Expert Rev Neurother; 2004 Jan; 4(1):53-60. PubMed ID: 15853615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
    Macaluso M; Kazanchi H; Preskorn SH
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.